Stay updated with breaking news from Sensor Enabled. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
North America to account for larger share in atrial fibrillation market during 2022–2028; growth driven by rising geriatric population, increasing occurrence of cardiovascular diseases, high accessibility to advanced technologies, growing development of innovative and technologically advanced products, and increasing healthcare expenditure
FlexAbility Ablation Catheter, Sensor Enabled secures FDA approval for an expanded indication following favorable study outcomes in treating complex heart condition
Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experienci...
/PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for...
Abbott announced today that a study showed its TactiCath ablation catheter often led to more than a year of freedom from AFib symptoms.